rIFNα-2b雾化吸入联合匹多莫德对疱疹性咽峡炎患儿的影响

Effect of the combination of rIFNα-2b aerosol inhalation with pidotimod on children with herpangina

目的研究探讨重组人干扰素-α2b(recombinant human interferonα-2b,rIFNα-2b)雾化吸入联合匹多莫德对疱疹性咽峡炎患儿、炎症因子、细胞免疫的治疗效果。方法以2020年3月—2021年3月在某医院儿科进行治疗的98例疱疹性咽峡炎患儿分为观察组和对照组各49例。对照组以匹多莫德治疗,观察组以rIFNα-2b雾化吸入联合匹多莫德治疗。结果观察组总有效率为91.84%(45/49),对照组总有效率为73.47%(36/49),两组治疗有效率差异有统计学意义(χ^(2)=5.765,P<0.05);观察组发热、疱疹、咽痛消退时间和住院时间均低于对照组,组间比较差异有统计学意义(t=6.208、5.151、4.081、4.688,P<0.05)。治疗后观察组炎症因子超敏C反应蛋白(hypersensitive C-reactive protein,hs-CRP)、单核细胞趋化蛋白-1(monocyte chemoattractant protein-1,MCP-1)、白细胞介素-4(interleukin-4,IL-4)水平均低于对照组(t=7.575、5.786、7.207,P<0.05)。治疗后观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组,组间比较差异有统计学意义(t=2.895、3.908、4.648、6.020,P<0.05)。两组患儿不良反应发生率为14.29%(7/49)、10.20%(5/49),差异无统计学意义(χ^(2)=0.380,P>0.05)。结论rIFNα-2b雾化吸入联合匹多莫德对疱疹性咽峡炎患儿治疗效果良好,能促进症状消退,减轻机体炎症反应,改善患儿细胞免疫功能,治疗安全性较好。

Objective To study the therapeutic efficacy of the combination of recombinant human interferonα-2b(rIFNα-2b)aerosol inhalation with pidotimod on children with herpangina,inflammatory factors and cellular immunity.Methods A total of 98 children with herpangina treated in the pediatric department of a hospital from March 2020 to March 2021 were divided into an observation group and a control group of 49 cases in each group.The control group was treated with pidotimod,and the observation group was treated with rlFNα-2b aerosol inhalation combined with pidotimod.Results The total effective rate was 91.84%(45/49)in the observation group and 73.47%(36/49)in the control group,the difference between the treatment effectiveness of the two groups was statistically significant(χ^(2)=5.765,P<0.05).The time to regression of fever,herpes,pharyngeal pain and hospitalization time in the observation group were lower than those in the control group,the differences were statistically significan between groups(t=6.208,5.151,4.081,4.688,P<0.05).After treatment,the levels of inflammatory factors such as hypersensitive C-reactive protein(hs-CRP),monocyte chemoattractant protein-1(MCP-1),and interleukin-4(IL-4)in the observation group were lower than those in the control group(t=7.575,5.786,7.207,P<0.05).After treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and CD8*was lower than that in the control group,the differences were statistically significan between groups(t=2.895,3.908,4.648,6.020,P<0.05).The incidence of adverse reactions in the two groups of children was 14.29%(7/49)and 10.20%(5/49)(χ^(2)=0.380,P>0.05),the difference was not statistically significant.ConclusionThe combination of rlFNα-2b aerosol inhalation with pidotimod has a good therapeutic effect on children with herpangina,can promote the regression of symptoms,reduce the body's inflammatory response,improve the children's cellular immune function,and has a good therapeutic safety.